Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
100%(5 trials)

Phase Distribution

Ph not_applicable
1
13%
Ph phase_2
3
38%
Ph phase_4
4
50%

Phase Distribution

0

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
3(37.5%)
Phase 4Post-market surveillance
4(50.0%)
N/ANon-phased studies
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(5)
Terminated(3)

Detailed Status

Completed5
Withdrawn3

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (37.5%)
Phase 44 (50.0%)
N/A1 (12.5%)

Trials by Status

completed563%
withdrawn338%

Recent Activity

0 active trials
Showing 5 of 8
completednot_applicable

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

NCT02725177
withdrawnphase_2

Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)

NCT00986960
withdrawnphase_4

ACTHAR Therapy for Central Nervous System Sarcoidosis

NCT02920710
completedphase_4

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

NCT01386554
completedphase_2

Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients

NCT01601236
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT02725177Not Applicable

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

Completed
NCT00986960Phase 2

Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)

Withdrawn
NCT02920710Phase 4

ACTHAR Therapy for Central Nervous System Sarcoidosis

Withdrawn
NCT01386554Phase 4

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

Completed
NCT01601236Phase 2

Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients

Completed
NCT03398018Phase 4

Repository Corticotropin Injection in Keratoconjunctivitis Sicca

Withdrawn
NCT01906658Phase 2

A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis

Completed
NCT01966718Phase 4

Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies.

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8